A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans

(2023) Yu-Luan Chen et al.   Neurology and Therapy

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia

(2022) Guangqing Xiao et al.   PHARMACEUTICAL RESEARCH

Safety and Effectiveness of SEP−363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study

(2021) Christoph U. Correll et al.   CNS SPECTRUMS

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856

(2021) Veronica Begni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

(2021) Seth C. Hopkins et al.   Translational Psychiatry

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

(2021) Gerald R. Galluppi et al.   CPT-Pharmacometrics & Systems Pharmacology

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

(2021) Seth C. Hopkins et al.   CLINICAL DRUG INVESTIGATION

Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats

(2021) Colleen Synan et al.   DRUG AND ALCOHOL DEPENDENCE

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

(2021) Nina Dedic et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study

(2021) Yu-Luan Chen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

(2021) Michele L. R. Heffernan et al.   ACS Medicinal Chemistry Letters

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

(2020) Michelle Kokkinou et al.   MOLECULAR PSYCHIATRY

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

(2020) Kenneth S. Koblan et al.   NEW ENGLAND JOURNAL OF MEDICINE

SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION

(2019) Nina Dedic et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

(2019) Kelly E. Caudle et al.   CTS-Clinical and Translational Science

The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine

(2018) Muh. Akbar Bahar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers

(2014) C. Briciu et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine

(2013) Akiko Mikami et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS